Christian S. Schade
2022
In 2022, Christian S. Schade earned a total compensation of $1.4M as Chairman and Chief Executive Officer at Aprea Therapeutics, a 58% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $281,500 |
|---|---|
| Option Awards | $581,672 |
| Salary | $328,417 |
| Stock Awards | $182,182 |
| Total | $1,373,771 |
Schade received $581.7K in option awards, accounting for 42% of the total pay in 2022.
Schade also received $281.5K in non-equity incentive plan, $328.4K in salary and $182.2K in stock awards.
Rankings
In 2022, Christian S. Schade's compensation ranked 2,419th out of 5,760 executives tracked by ExecPay. In other words, Schade earned more than 58.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,419 out of 5,760 | 58th |
Division Manufacturing | 1,326 out of 3,136 | 58th |
Major group Chemicals And Allied Products | 595 out of 1,422 | 58th |
Industry group Drugs | 549 out of 1,323 | 59th |
Industry Pharmaceutical Preparations | 397 out of 969 | 59th |
Source: SEC filing on July 11, 2023.
Schade's colleagues
We found four more compensation records of executives who worked with Christian S. Schade at Aprea Therapeutics in 2022.
News
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020